Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines

Rita Ötvös, Henriette Skribek, Lorand L. Kis, Annunziata Gloghini, Laszlo Markasz, Emilie Flaberg, Staffan Eksborg, Jozsef Konya, Lajos Gergely, Antonino Carbone, Laszlo Szekely

Research output: Contribution to journalArticlepeer-review


Background: Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men with severe immunosuppression and other HHV8-associated diseases such as Kaposi's sarcoma (KS). The prognosis for those infected is poor, with a median survival of less than 6 months in most cohorts. Sustained complete remission is rare. High-dose chemotherapy regimens are used to improve remission rate and survival. The aim of the present study was to compare the drug sensitivity pattern of the available primary effusion (body cavity based) lymphoma-derived cell lines in order to find additional, potentially effective drugs that are not included in current chemotherapy treatment protocols.Methods: We have analyzed 11 cell lines against 27 frequently used cytostatic drugs in short term (3 days) survival assays using automated high throughput confocal microscopy.Results: All cell lines showed a distinct, individual drug sensitivity pattern. Considering the in vitro used and clinically achieved drug concentration, Vinorelbine, Paclitaxel, Epirubicin and Daunorubicin were the most effective drugs.Conclusions: We suggest that inclusion of the above drugs into PEL chemotherapy protocols may be justified. The heterogeneity in the drug response pattern however indicated that assay-guided individualized therapy might be required to optimize therapeutic response.

Original languageEnglish
Article number441
JournalBMC Cancer
Publication statusPublished - Oct 12 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics


Dive into the research topics of 'Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines'. Together they form a unique fingerprint.

Cite this